Attached files
file | filename |
---|---|
EX-99.2 - EX-99.2 - Dova Pharmaceuticals Inc. | a18-13054_1ex99d2.htm |
EX-99.1 - EX-99.1 - Dova Pharmaceuticals Inc. | a18-13054_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2018
Dova Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
|
001-38135 |
|
81-3858961 |
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
|
|
|
240 Leigh Farm Road, Suite 245 |
|
27707 |
Registrants telephone number, including area code: (919) 748-5975
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 7.01 Regulation FD Disclosure.
On May 21, 2018, Dova Pharmaceuticals, Inc. (the Company) issued a press release announcing the U.S. Food and Drug Administration (FDA) has completed their Priority Review and approved DOPTELET® (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Also, on May 21, 2018, the Company will conduct a conference call and live audio webcast with slide presentation to discuss these matters. A copy of the slide presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 and the presentation furnished as Exhibit 99.2 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and is not incorporated by reference into any of the Companys filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
Item 8.01 Other Events.
On May 21, 2018, Company announced FDA has completed their Priority Review and approved DOPTELET (avatrombopag) for the treatment of thrombocytopenia in adult patients with CLD who are scheduled to undergo a procedure.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
99.1 |
|
|
99.2 |
|